Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are evaluating the effects of the medicine imlunestrant LY3484356 on premenopausal women with early estrogen receptor-positive, HER2-negative breast cancer. The study includes two groups one to compare imlunestrant with and without ovarian suppression against tamoxifen over up to 29 days, and another to assess imlunestrants effects on the ovaries compared to tamoxifen over up to 6 months. This phase 2 trial aims to understand treatment impacts on breast cancer cells and ovarian function. Participants receive different treatments depending on their group in Cohort 1, some take imlunestrant orally alone, some take it with subcutaneous goserelin to suppress ovarian function, and others take oral tamoxifen. In Cohort 2, participants take either oral imlunestrant or oral tamoxifen without ovarian suppression. Treatments last up to 29 days for Cohort 1 and up to 6 months for Cohort 2. During the study, participants will provide tumor samples before and during treatment, and researchers will monitor tumor markers such as Ki-67, estrogen receptor, and progesterone receptor expression. They will also track ovarian cysts over 180 days. The study includes assessments of organ function and performance status, with participant involvement lasting up to 6 months depending on the cohort.
Actively Recruiting
Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Researchers are studying metastatic colorectal carcinoma mCRC patients who have a specific BRAFV600E mutation, which is linked to poorer outcomes compared to those without it. This mutation leads to shorter survival times after initial treatments, prompting the need for new therapy combinations. This research aims to observe how the drugs encorafenib and cetuximab work together in real-world settings for patients who have already received prior systemic therapies. This non-interventional, prospective, longitudinal study focuses on patients treated with encorafenib plus cetuximab following prior systemic therapy. The study collects data on treatment effectiveness, safety, and quality of life among a broader patient population in Germany, Austria, and Switzerland. Patients may have started treatment up to three months before joining the study or plan to start soon, and the study observes their outcomes without influencing treatment decisions. Participants will be monitored through data collection on their disease and treatment profiles, including patient and physician assessments, adverse events, and treatment details. The main outcome measured is overall survival at 12 months after starting treatment. Additional information gathered includes treatment duration, dose intensity, interruptions, and patient-reported quality of life using questionnaires. Safety and tolerability are also evaluated throughout treatment, with follow-up averaging nine months.
Actively Recruiting
Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.
Actively Recruiting
Researchers are studying patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer who have gBRCA12 mutations. This study aims to evaluate whether adding elacestrant, a new oral estrogen receptor blocker, to the standard olaparib treatment can improve progression-free survival compared to olaparib alone. This is a phase II, multi-center, randomized, open-label study with patients assigned in a 21 ratio to two different treatment groups. Participants randomized to Arm A will receive 600 mg of olaparib daily plus 400 mg of elacestrant daily, while those in Arm B will receive 600 mg of olaparib daily alone. Treatment will continue until disease progression, unacceptable side effects, patient withdrawal, or the study ends. Pre- and perimenopausal women, as well as men, will also receive a GnRH analogue at least two weeks before treatment starts. Dose modifications are provided for managing specific side effects. During the study, blood tests will be done at the start of each treatment cycle, and imaging scans along with quality of life assessments will be performed every three months or if disease progression is suspected. Researchers will measure progression-free survival, overall survival, treatment failure times, response rates, clinical benefit, adverse events, and treatment compliance. Participants may remain in the study for up to 48 months, with an average treatment duration of about 12 months per patient.
Actively Recruiting
This research aims to evaluate intestinal Levodopa plus entacapone therapy Lecigon4 in patients with Parkinsons disease who require this treatment based on existing guidelines. The study is a Phase III randomized controlled trial comparing Lecigon4 to the best available oral medication. The primary goal is to assess whether Lecigon4 is superior in reducing hyperdopaminergic symptoms measured by the Ardouin Behavioral Scale after six months. Participants are randomly assigned to one of two groups those continuing best oral medication and those receiving Lecigon4 as an intestinal gel combining levodopa, carbidopa, and entacapone. The trial uses a parallel group design with a waiting list component. Treatment is given according to established dosing criteria and patients are followed for at least six months to monitor effects. During the study, participants undergo regular assessments including behavioral evaluations with the Ardouin Behavioral Scale to track hyperdopaminergic syndrome changes. Safety and adherence to therapy are monitored throughout. The trial excludes patients with severe cognitive impairment or other contraindications. Total participation covers screening, treatment, and follow-up up to six months, with the primary outcome measured at that time.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of the Magseed Pro marker and Sentimag Gen3 system for marking suspicious or biopsy-proven positive axillary lymph nodes and soft tissue breast lesions, including cancerous and precancerous changes. It is a multicenter, international, open-label study involving patients with breast andor lymph node conditions requiring surgical excision. The study is focused on providing prospective evidence for these devices in guiding surgical removal. Participants will have the Magseed Pro marker placed percutaneously under imaging guidance to mark either axillary lymph nodes or breast lesions targeted for surgical removal. The Sentimag Gen3 system is then used to localize the marker during surgery, helping surgeons accurately remove the targeted tissue. The trial plans to enroll 224 patients, split evenly between those with markers placed in lymph nodes and those with markers placed in breast lesions. Each participants involvement lasts approximately 1 to 38 weeks from enrollment. During the study, researchers will track marker retrieval rates within the excised tissue at the time of surgery, monitor tissue responses, and record any device-related adverse events throughout the study duration. Other assessments include ease of marker placement and localization, re-excision rates, and marker position stability. Participants will undergo imaging and surgical procedures as part of their routine care, with follow-up visits as needed to monitor outcomes and safety over an average of 38 weeks.
Actively Recruiting
Researchers are evaluating whether patients with hormone-receptor positive, HER2-negative early breast cancer HRHER2- eBC who have intermediate to high risk of recurrence may benefit from an initial 5-year treatment with elacestrant, with or without a CDK 46 inhibitor, followed by standard endocrine therapy ET for an additional 0 to 2.5 years. This is compared to the current standard of care ET lasting between 5 and 7.5 years, with or without CDK 46 inhibitors. The study is designed for patients identified by genomic tests like Oncotype DX and response to preoperative endocrine therapy, aiming to improve long-term survival by targeting resistance mechanisms such as ESR1 mutations. Participants are randomly assigned to one of two groups one receiving elacestrant orally for 5 years, possibly combined with ribociclib a CDK 46 inhibitor for 3 years if indicated, and the other receiving standard endocrine treatments for 5 to 10 years with optional CDK 46 inhibitors as decided by their doctor. The treatments are evaluated in a parallel study design. The trial builds on previous findings in metastatic breast cancer and early breast cancer studies exploring endocrine therapy responses and genomic risk assessments. Throughout the study, participants undergo regular clinical assessments, including tumor pathology reviews, laboratory tests, and electrocardiograms to monitor safety and treatment effects. Researchers measure outcomes such as 5-year invasive disease-free survival and other survival metrics. Participants must comply with contraception requirements and be followed for treatment adherence and safety until study completion, which is planned for up to 2033.
1-10 of 20
1